Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Discovery and Development of Innovative Drug
100,0
%
| 10 | 100,0 % | 10 | 100,0 % | -1,37% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 10 | 100,0 % | 10 | 100,0 % | -1,37% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29/03/16 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26/07/22 |
Chief Tech/Sci/R&D Officer | - | 03/01/22 | |
Chief Tech/Sci/R&D Officer | - | 13/08/19 | |
Robert Martell
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/09/11 |
Mark W. Noel
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/03/01 |
Rachel Blasbalg
HRO | Human Resources Officer | - | 01/01/04 |
Dora Ferrari
PRN | Corporate Officer/Principal | - | 03/01/21 |
Nancy Soohoo
LAW | General Counsel | - | 01/01/03 |
Jonathan Zung
PRN | Corporate Officer/Principal | 59 | 01/05/23 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 01/11/03 |
Martyn Greenacre
CHM | Chairman | 82 | 14/02/00 |
James Dentzer
CEO | Chief Executive Officer | 57 | 29/03/16 |
Marc Rubin
BRD | Director/Board Member | 69 | 03/06/10 |
Robert Martell
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/09/11 |
Anne Borgman
BRD | Director/Board Member | 56 | 01/10/22 |
John Hohneker
BRD | Director/Board Member | 64 | 02/12/21 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 5 894 085 | 5 883 204 ( 99,82 %) | 0 | 99,82 % |
Coordinate società
Settore
Variaz. 1 gen. | Capi. | |
---|---|---|
+29,03% | 48,16 Mrd | |
-0,10% | 41,73 Mrd | |
+43,45% | 41,03 Mrd | |
-5,26% | 28,77 Mrd | |
+11,48% | 25,59 Mrd | |
-22,74% | 18,96 Mrd | |
+9,06% | 12,92 Mrd | |
+30,01% | 12,03 Mrd | |
-1,51% | 11,77 Mrd |